Nuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual Meeting
Rhea-AI Summary
Nuwellis (Nasdaq: NUWE) highlighted a University of Iowa case study presented at the 46th ISHLT Annual Meeting (April 22–25, 2026) on pediatric ultrafiltration for chemotherapy‑induced dilated cardiomyopathy with recurrent fluid overload.
The poster evaluated feasibility, safety, and clinical impact of Aquadex ultrafiltration when diuretics failed, and notes the device is indicated for patients ≥20 kg for temporary or extended continuous ultrafiltration under trained provider supervision.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed single-day moves (e.g., TIVC +7.69%, NAOV -1.95%), and the momentum scanner shows no peers moving in tandem with NUWE, pointing to stock-specific dynamics around this news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Patent allowance | Positive | -4.3% | USPTO Notice of Allowance for dual lumen midline catheter ultrafiltration patent. |
| Apr 23 | Conference participation | Positive | +3.9% | Planned AATS meeting participation to showcase Aquadex and engage cardiac surgeons. |
| Apr 21 | Product update | Positive | -0.9% | Aquadex software update enhancing precision and usability, especially for pediatrics. |
| Apr 16 | Commercial hires | Positive | -2.9% | Return of three commercial and clinical staff to accelerate Aquadex adoption. |
| Apr 09 | IR engagement | Neutral | +0.0% | Retention of CORE IR to expand public relations and investor communications. |
Recent positive operational news has often been followed by flat to negative next-day moves, suggesting a pattern of selling or indifference into good headlines.
Over April 2026, Nuwellis issued multiple updates centered on its Aquadex ultrafiltration platform and commercial rebuild. These included a software upgrade improving pediatric fluid-management precision on April 21, commercial team rehires on April 16, and engagement of CORE IR for outreach on April 9. A patent Notice of Allowance on April 28 and ongoing conference participation support the same clinical and commercial theme. Despite generally constructive content, share reactions often skewed flat to negative, framing today’s scientific-poster news within a cautious trading backdrop.
Regulatory & Risk Context
An effective S-3 resale registration filed on February 3, 2026 covers up to 4,279,325 warrant-related shares. Nuwellis would not sell shares directly under this filing but may receive up to $28 million in cash if all registered warrants are exercised, alongside potential shareholder dilution from those exercises.
Market Pulse Summary
This announcement spotlights further clinical experience with Aquadex in complex pediatric cardiorenal care, using precision ultrafiltration when diuretics are insufficient. It complements recent efforts to enhance the platform and expand clinical adoption. Investors monitoring the story may focus on how such case reports translate into broader utilization, revenue trends from the $8.3 million 2025 base, progress on Nuwellis’ going-concern plans, and use of the warrant-related resale registration that could generate up to $28 million in cash.
Key Terms
ultrafiltration medical
precision ultrafiltration medical
dilated cardiomyopathy medical
cardiorenal medical
ultrafiltration therapy medical
AI-generated analysis. Not financial advice.
Poster presentation showcased continued advancement of Aquadex therapy in pediatric applications, underscoring continued need for adoption in fluid management in pediatric heart failure
MINNEAPOLIS, April 29, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights a case study presented by the University of Iowa Stead Family Children's Hospital at the 46th Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), held April 22–25, 2026, in Toronto, Canada. At the event, independent investigators presented poster, “Therapeutic Ultrafiltration to Treat Symptomatic Pediatric Heart Failure,” which explored the use of ultrafiltration in a pediatric patient with chemotherapy-induced dilated cardiomyopathy and recurrent fluid overload. The study was designed to evaluate its feasibility, safety, and clinical impact when diuretics and medical management did not prevent hospital readmissions.
“The case presented on the poster reinforces the growing body of evidence supporting precision ultrafiltration as an important tool in managing fluid overload in complex pediatric cardiorenal patients. We continue to work with practitioners to help adopt the Aquadex SmartFlow® pediatric indication and these types of presentations are supportive of our ongoing work toward establishing a standard of care for these patients,” said Nuwellis’ CEO John Erb. “The use of Aquadex in the case study not only indicates safe and effective fluid management, but also improving clinical status pre operative and improving outcomes post cardiac transplant. The scientific dialogue on the importance and impact of fluid management in the pediatric setting was an important topic discussed at ISHLT.”
Nuwellis’ Aquadex ultrafiltration therapy is designed to provide controlled, precise fluid removal for patients with fluid overload when diuretics are insufficient, supporting improved clinical management in heart failure and related conditions. It is indicated for continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.
ISHLT is a leading global forum that brings together clinicians and researchers focused on advanced heart and lung disease, transplantation, and mechanical circulatory support, highlighting cutting-edge science and innovation in the field. Poster presentations at ISHLT provide an important opportunity for clinicians and researchers to share emerging data and engage in scientific exchange with the global transplant and heart failure community.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit www.nuwellis.com.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
CORE PR
media@nuwellis.com
